Market Blog » The Arora Report Stock Market News

MORE GAINS AHEAD ON THIS SOFTWARE STOCK – 1247% GAIN

March 10, 2021

MongoDB (MDB) is a database software stock. It is long from $24. It is trading at $323.33 as of this writing. This represents a 1247% gain. At The Arora Report, we advocate diversifying by time frames ranging from very long term to very, very short term. Please see Trade Management Guidelines for six different time frames. MDB illustrates the power of long term investing. MDB remains a buyout candidate. To date, 162 of The Arora Report portfolio companies have been bought out producing a fortune for long-time subscribers. Zones This is a very long term position. The target zone is

REDUCE CASH – PRUDENT INVESTORS PAY ATTENTION TO THE BIGGEST DIVERGENCE IN 28 YEARS

March 9, 2021

To gain an edge, this is what you need to know today. Reduce Cash The Arora Report gave a sell signal one day before the market top. Of special note are our statements, It is time to take more partial profits or full profits depending upon individual situations. It is imperative to take more partial profits on the stocks that are based on the momo strategy. Since then ETF ARKK, the favorite of the momo crowd has fallen 27.98% and was down 33% intraday. Many momo stocks have fallen 40 – 70%. It is time to judiciously reduce cash by

KEY TO THE STOCK MARKET IS BONDS – BETS AGAINST BONDS RISE

March 8, 2021

Key To The Stock Market Please click here for a chart of 7-10 year Treasury Bond ETF (IEF). Note the following: The chart is of ETF IEF as opposed to a chart of yield because IEF is the easiest for most investors to watch. Bonds move inverse to interest rates. In plain English, when interest rates go higher, bonds fall. Our call has been that this stock market is a bubble. The bubble is being inflated with heavy borrowing, money printing and low interest rates artificially enforced by the Fed. We have repeatedly written that the biggest risk to this stock market is if the Fed

WEEKLY STOCK MARKET DIGEST: HEAD AND SHOULDERS PATTERN FORMED – BIDEN AND POWELL GONE TOO FAR

March 7, 2021

Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report. Please scroll down for the section ‘Protection Bands and What To Do Now.’ BIDEN AND POWELL GONE TOO FAR – HEAD AND SHOULDERS FORMED March 5, 2021 To gain an edge, this is what you need

WOULD YOU HAVE LIKED A SELL SIGNAL ONE DAY BEFORE THE STOCK MARKET TOPPED?

March 5, 2021

Would you have liked a sell signal one day before the market topped? Those with portfolios heavy in momentum stocks and some options have lost 50 – 70% of their portfolios since the top. Those with portfolios mostly in near-term options have lost 90%. In terms of dollars, how much difference would it have made to you if you had a sell signal one day before the market topped? The Arora Report subscribers received a sell signal on February 11, 2021, one day before the market topped. The Chart Please click here for an annotated chart of Nasdaq 100 ETF

BIOLOGICAL TESTING PRODUCTS COMPANY LMNX BECOMES A BUYOUT TARGET

March 3, 2021

Luminex Corporation (LMNX) has become a buyout target. There is an 80% probability of a deal ultimately happening. LMNX is trading at $32.09 as of this writing. The most likely acceptable bid is in the zone of $38 to $42. If a bidding war erupts, the stock can go higher. In the world of investing there no free lunch. The issue here is that the stock can easily trade in the range of $21 to $34 in the interim. A good way to handle this situation is to scale in with small tranches such as 5%. The maximum recommended quantity

MORE GAINS AHEAD – 63% GAIN ON THIS SUPPLIER OF A KEY COMPONENT FOR VACCINE

March 3, 2021

Maravai LifeSciences (MRVI) is long from $25.84. MRVI is trading at $42.25 as of this writing. This represents a gain of 63% in a short time. MRVI reported earnings significantly better than the consensus. We have previously written that the target zone was likely to be raised. MRVI supplies a key component of the coronavirus vaccine produced by Pfizer (PFE) and BioNTech (BNTX). The vaccine should provide a sharp increase in revenue. The company also has a diversified product portfolio. Zones For those following the Good Way, the Buy Now rating is ‘NO.’ For those following the Best Way the buy

PAY ATTENTION: TOP REGULATOR ‘VERY WORRIED’ ABOUT THE STOCK MARKET BUBBLE

March 2, 2021

To gain an edge, this is what you need to know today. Very Worried Please click here for a chart of S&P 500 ETF (SPY) which represents the benchmark for the stock market index (SPX). Note the following: The top banking regulator is ‘very worried’ about the stock market bubble in the U. S. You may be thinking how could it be because the Fed is inflating the bubble and the Fed is the top banking regulator in the U. S. Top regulators typically make a policy of not commenting on other countries. Yet, Guo Shuqing, chairman of the China